Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 18, 2014 Global HIV ... pharma report announced by Reportstack. The rate of HIV infection ... on a declining note at a positive rate across the ... from 2.3 million in 2005 to 1.5 in 2013, with ... cause for such drastic changes in the infection rates has ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, ... company pioneering the manufacturing and marketing of innovative therapies ... the Company is providing a second notice of TNI ... In making the announcement, Noreen Griffin , founder ... in advance for your participation in the Annual Meeting. ...
(Date:8/18/2014)... August 2014 Vier führende deutsche ... klinische Studie auf, in der eine Intraokularlinse ... das Sehvermögen bei allen Entfernungen verbessern, so ... keine Lese- oder Gleitsichtbrille mehr benötigen. Die ... FluidVision Accommodating Intraocular Lens (FluidVision akkomodative ...
(Date:8/16/2014)... a way to make atomic-force microscope probes 20 times ... as the weight of an individual virus. , The ... (ANU), hinges on using laser beams to cool a ... level of sensitivity achieved after cooling is accurate enough ... virus that is 100 billion times lighter than a ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4Laser makes microscopes way cooler 2
... , , , ... Healthcare today released new survey results revealing that 85 percent of ... concern. Yet, when asked about testing their children for allergies, ... options available. Furthermore, more than one-third were not familiar with the ...
... , London, July 20 There has been a ... and biotechnology space. While the economic downturn and related credit crunch ... M&A mania, which has including four mega M&As in the first ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , "The ...
... , , COLUMBIA, Md., July 17 ... DHA, Martek Biosciences (Nasdaq: MATK ), announced today that it ... Food Chain and Animal Health (SCFCAH) of the European Union for additional ... , This is a significant action that will provide ...
Cached Biology Technology:American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 2American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 3American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 4American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals 5Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 2EU Committee Approves New Food Applications for Martek's life'sDHA(TM) 3
(Date:8/19/2014)... and other science courses are increasingly being asked ... they have a new textbook to help them ... this month by Princeton Press and co-authored by ... Biological Synthesis (NIMBioS), teaches readers about basic mathematical ... explore and explain biological phenomena. , Suitable for ...
(Date:8/19/2014)... a glass of fizzy soda knows that bubbles can ... finding with wide industrial applications, Princeton researchers have demonstrated ... the liquid as well. , "It is well known ... surprised, and fascinated, to discover that when we covered ... oil droplets into the water," said Howard Stone, the ...
(Date:8/19/2014)... 19 August 2014: An engineer at the University of ... having a brain to communicate with the body. , ... L Mahadevan, has developed a mathematical model for earthworms ... how these soft bodied animals get around. , The ... pattern generator (CPG) which states that the central brain ...
Breaking Biology News(10 mins):New textbook introduces undergraduates to mathematics for the life sciences 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Secrets of how worms wriggle uncovered 2
... TXService learning involves the incorporation of community service into ... In the service learning model, students participate in ,real ... community. Researchers T.M. Waliczek and J.M. Zajicek reported on ... horticulture course in HortTechnology . The team found ...
... June 23, 2011 UT Southwestern Medical Center ... signaling pathway in Huntington,s disease, a finding that may ... slow the progression of degenerative nerve disorders. "Our ... disease treatment and possibly for other neurodegenerative diseases," said ...
... began working with legendary drug developer Paul Janssen, founder of ... an effort to create new and potent drugs to fight ... second anti-HIV drug that came from this collaboration., "For ... countless obstacles must be overcome," said Eddy Arnold, Board of ...
Cached Biology News:Service projects increase learning, social impact for undergrads 2Compound may provide drug therapy approach for Huntington's disease 2Rutgers laboratory helped to create new HIV drug 2Rutgers laboratory helped to create new HIV drug 3